Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

As 23andMe struggles, another genetic testing company bets on drug discovery

Two years ago, GeneDx was teetering. The genetic testing company had laid off 33% of its staff, shares were down 90% from a year prior

December 5, 2024

New findings shed light on AI’s potential in clinical settings

Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model solved medical quiz questions-;designed to test health professionals’ ability to

July 23, 2024

From the editor: Our final edition of Endpoints MarketingRx

To our MarketingRx readers — Last week, we made the decision to shut down Endpoints MarketingRx. Over the last year, Endpoints News has put more

May 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.